Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard's portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 130 patients across five disease areas. These programs include Strimvelis, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/14/18 | $150,000,000 | Series C |
ArrowMark Partners Cormorant Asset Management Deerfield Management Company, L.P.  Driehaus Capital Management Foresite Capital Ghost Tree Capital Group Medison Venutres Perceptive Advisors RA Capital Management Sphera Global Healthcare Temasek Venrock | undisclosed |
